Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
PR Newswire
Report Store
UsernamePublicRestriction
Tags:
Business Strategies Commercial Innovation

Medtronic Lays Out Plans To Achieve 5%+ Annual Growth

  • News

Executive Summary

The medtech giant offered additional details on its ongoing restructuring plan intended to make the company more competitive.

You may also be interested in...



JPM 2021: Medtronic, Biogen, Edwards LifeSciences, Guardant Health, Illumina

The annual J.P. Morgan Healthcare Conference includes presentations from many major medtech companies outlining their growth strategies and expectations for 2021. Here are some of the highlights from the first day of the meeting.

Medtronic Cardiovascular Chief Coyle To Lead iRhythm

Sean Salmon, the head of Medtronic’s diabetes business, will take over the leadership of the company’s cardiovascular business effective 1 January.

Medtronic Expands ENT Portfolio With Ai Biomed Acquisition, NIM Vital Clearance

Ai Biomed’s PTeye helps to identify parathyroid tissue during thyroid surgery. Medtronic ENT also announced the FDA clearance of its NIM Vital electromyographic system for nerve monitoring during surgery.

Table

View full table

Related Content

Medtech Insight
Medtech Insight

Topics

Tags:
Business Strategies Commercial Innovation
UsernamePublicRestriction

Register

LL1129552

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By